Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research note issued to investors on Thursday.

Separately, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Price Performance

SUPN traded down $0.32 on Thursday, reaching $31.74. The company's stock had a trading volume of 764,654 shares, compared to its average volume of 502,301. Supernus Pharmaceuticals has a 1 year low of $25.53 and a 1 year high of $40.28. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of 29.66 and a beta of 0.90. The business's 50 day moving average is $37.12 and its 200 day moving average is $35.37.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Jonathan Rubin sold 927 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is owned by corporate insiders.

Remove Ads

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of large investors have recently made changes to their positions in SUPN. Barclays PLC boosted its holdings in shares of Supernus Pharmaceuticals by 88.3% during the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock worth $3,393,000 after purchasing an additional 51,005 shares during the period. Segall Bryant & Hamill LLC acquired a new position in shares of Supernus Pharmaceuticals during the 3rd quarter valued at about $791,000. Geode Capital Management LLC raised its position in shares of Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock valued at $46,218,000 after purchasing an additional 74,438 shares during the period. Franklin Resources Inc. lifted its position in Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock worth $987,000 after acquiring an additional 2,121 shares during the last quarter. Finally, Empowered Funds LLC bought a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $1,498,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.